Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Other Revenue	-	-	-	-0	0
Revenue	3,615	3,564	4,495	1,338	526.97
Revenue Growth (YoY)	-10.50%	-20.71%	235.98%	153.88%	-
Cost of Revenue	2,366	2,350	3,107	1,210	719.82
Gross Profit	1,249	1,214	1,388	128.31	-192.84
Selling, General & Admin	3,250	3,366	3,106	2,184	1,492
Research & Development	884.19	704.29	261.84	567.73	526.69
Other Operating Expenses	65.24	56.84	51.24	37.1	24.25
Operating Expenses	5,765	5,524	4,293	3,459	2,485
Operating Income	-4,516	-4,309	-2,905	-3,331	-2,678
Interest Expense	-179.83	-184.48	-1,606	-2,090	-1,152
Interest & Investment Income	529.66	407.45	282.76	212.78	20.73
Currency Exchange Gain (Loss)	77.65	141.55	-9.42	-3.15	1.26
Other Non Operating Income (Expenses)	15.32	23.28	-96.18	-4,586	1,187
EBT Excluding Unusual Items	-4,073	-3,922	-4,334	-9,798	-2,621
Gain (Loss) on Sale of Investments	-	-	18.84	-	-
Gain (Loss) on Sale of Assets	-81.74	-81.74	-727.97	62.23	-
Pretax Income	-4,155	-4,003	-5,044	-9,735	-2,621
Net Income	-4,155	-4,003	-5,044	-9,735	-2,621
Net Income to Common	-4,155	-4,003	-5,044	-9,735	-2,621
Shares Outstanding (Basic)	14	14	8	5	0
Shares Outstanding (Diluted)	14	14	8	5	0
Shares Change (YoY)	49.15%	78.92%	52.83%	2400.20%	-
EPS (Basic)	-291.16	-292.81	-660.00	-1947.00	-13103.03
EPS (Diluted)	-291.16	-292.81	-660.00	-1947.00	-13103.03
Free Cash Flow	-6,527	-7,363	-3,936	-4,487	-4,783
Free Cash Flow Per Share	-457.38	-538.52	-515.08	-897.29	-23915.53
Gross Margin	34.55%	34.06%	30.88%	9.59%	-36.59%
Operating Margin	-124.92%	-120.91%	-64.63%	-248.95%	-508.10%
Profit Margin	-114.93%	-112.32%	-112.20%	-727.66%	-497.27%
Free Cash Flow Margin	-180.54%	-206.57%	-87.56%	-335.35%	-907.62%
EBITDA	-3,038	-2,933	-1,799	-2,468	-2,064
EBITDA Margin	-84.02%	-82.29%	-40.01%	-184.45%	-
D&A For EBITDA	1,478	1,376	1,106	862.95	614.04
EBIT	-4,516	-4,309	-2,905	-3,331	-2,678
EBIT Margin	-124.92%	-120.91%	-64.63%	-248.95%	-
Advertising Expenses	-	322.92	153.05	126.54	69.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.